Preferred Stock Offerings
By Preferred Stock Channel Staff, updated Fri, March 29, 1:54 AM
This Slide: #227 of 619 |
Slide #227. Fortress Biotech, Inc. — Preferred Stock Offering
Company:
Fortress Biotech, Inc. (NASDAQ:FBIO)
Date announced:
11/1/2017
Shares Offered:
1,000,000
Date of Pricing:
11/7/2017
Price Per Share:
$25.00
Preferred Stock Offering Details:
Fortress Biotech, Inc. (Nasdaq:FBIO) ("Fortress"), a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and biotechnology products, today announced that it intends to offer and sell shares of its Series A Cumulative Redeemable Perpetual Preferred Stock in an underwritten public offering. All of the shares to be sold in the offering will be offered by Fortress. In addition, Fortress intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares offered in the public offering. The Series A Preferred Stock has received an "A-" investment-grade rating from Egan-Jones Rating Co., an independent, unaffiliated rating agency. -updated 11/7- Fortress Biotech, Inc. (Nasdaq:FBIO) ("Fortress"), a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and biotechnology products, today announced that it has priced an underwritten public offering of one million shares of its 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock at a price of $25.00 per share, with expected gross proceeds to Fortress of $25 million. In addition, Fortress has granted the underwriters a 30-day option to purchase up to 150,000 additional shares at the public offering price, less underwriting discounts and commissions. The offering is expected to close on November 14, 2017, subject to customary closing conditions. The Series A Preferred Stock has received an "A-" investment-grade rating from Egan-Jones Rating Co., an independent, unaffiliated rating agency.
Fortress Biotech is a biopharmaceutical company focused on acquiring, developing and commercializing pharmaceutical and biotechnology products and product candidates. Through its partner company, Co. markets dermatology products including Qbrexza®, which is a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane® (isotretinoin) capsule, which is an oral capsule for the treatment of severe recalcitrant nodular acne; Ximino® (minocycline hydrochloride), which is an oral minocycline drug for the treatment of moderate to severe acne; as well as Targadox® (doxycycline hyclate), which is an oral doxycycline drug for adjunctive therapy for severe acne.
Preferred: FBIOP
Open the FBIO Page at Preferred Stock Channel »
|
Open the FBIO Page at Preferred Stock Channel (in a new window) »
Free FBIO Email Alerts: Get Dividend Alerts Get SEC Filing Alerts |
Strong Buy (4.00 out of 4) 92nd percentile
(ranked higher than approx. 92% of all stocks covered)
Based on data provided by Zacks Investment Research via Quandl.com |
|